C
Campbell D. Joyner
Researcher at Sunnybrook Health Sciences Centre
Publications - 47
Citations - 21365
Campbell D. Joyner is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Stroke & Fondaparinux. The author has an hindex of 31, co-authored 47 publications receiving 19772 citations. Previous affiliations of Campbell D. Joyner include University of British Columbia & University of Toronto.
Papers
More filters
Journal ArticleDOI
Irbesartan in Patients with Atrial Fibrillation
Salim Yusuf,Jeff S. Healey,J Pogue,Susan Chrolavicius,Marcus Flather,Robert G. Hart,S H Hohnloser,Campbell D. Joyner,Pfeffer,Stuart J. Connolly,Luc De Roy +10 more
TL;DR: There was no benefit of irbesartan in preventing hospitalization for atrial fibrillation or atrialfibrillation recorded on 12-lead electrocardiography, nor was there a benefit in a subgroup that underwent transtelephonic monitoring.
Journal ArticleDOI
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes
Andrzej Budaj,John W. Eikelboom,John W. Eikelboom,Shamir R. Mehta,Shamir R. Mehta,Rizwan Afzal,Susan Chrolavicius,Jean-Pierre Bassand,Keith A.A. Fox,Lars Wallentin,Ron J.G. Peters,Christopher B. Granger,Campbell D. Joyner,Salim Yusuf,Salim Yusuf +14 more
TL;DR: Bleeding in patients with ACS is a powerful determinant of fatal and non-fatal outcomes and reducing the risk of bleeding using a safer anticoagulant strategy during the first 9 days is associated with substantial reductions in morbidity and mortality.
Journal ArticleDOI
Patient prosthesis mismatch is rare after aortic valve replacement: valve size may be irrelevant.
Naoji Hanayama,George T. Christakis,Hari R. Mallidi,Campbell D. Joyner,Stephen E. Fremes,Christopher D. Morgan,Peter R.R Mitoff,Bernard S. Goldman +7 more
TL;DR: Severe patient-prosthesis mismatch is rare after aortic valve replacement and the size of valve implanted do not influence left ventricular mass index or intermediate-term survival.
Journal ArticleDOI
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial
Hans-Christoph Diener,John W. Eikelboom,Stuart J. Connolly,Campbell D. Joyner,Robert G. Hart,Gregory Y.H. Lip,Martin O'Donnell,Stefan H. Hohnloser,Graeme J. Hankey,Olga Shestakovska,Salim Yusuf +10 more
TL;DR: In patients with atrial fibrillation, apixaban is similarly effective whether or not patients have had a previous stroke or TIA, and the absolute benefits might be greater in these patients.
Journal ArticleDOI
Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
John W. Eikelboom,Martin O'Donnell,Salim Yusuf,Rafael Diaz,Greg C. Flaker,Robert G. Hart,Stefan H. Hohnloser,Campbell D. Joyner,Jack Lawrence,Prem Pais,Janice Pogue,David Synhorst,Stuart J. Connolly +12 more
TL;DR: By evaluating the use of apixaban as a replacement for ASA in AF patients who are not treated with a VKA, the AVERROES study is addressing an important unmet clinical need.